Retrospective evaluation of cetuximab-related adverse events from claims databases--methodological concerns

Ann Oncol. 2010 Aug;21(8):1731-1732. doi: 10.1093/annonc/mdq327. Epub 2010 Jul 6.

Authors

S Maier¹, G Peltz², J R Penrod³, K P Sugarman⁴

Affiliations

¹ Oncology Medical Strategy, Bristol-Myers Squibb, Plainsboro, NJ. Electronic address: sabine.maier@bms.com.
² Global Health Outcomes-Oncology, Eli Lilly and Company, Indianapolis, IN.
³ Oncology Health Outcomes Research, Bristol-Myers Squibb, Plainsboro, NJ.
⁴ Oncology Business Unit, Eli Lilly and Company, Indianapolis, IN, USA.

PMID: 20605932
DOI: 10.1093/annonc/mdq327

No abstract available

Publication types

Comment
Letter
Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Monoclonal / adverse effects*
Antibodies, Monoclonal, Humanized
Antineoplastic Agents / adverse effects*
Cetuximab
Database Management Systems*
Humans
Insurance Claim Review*
Retrospective Studies

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antineoplastic Agents
Cetuximab